James Bone, PhD
President & Co-founder
Jim earned a Bachelor of Science degree from the UNC Chapel Hill and a Ph.D. from Baylor College of Medicine. He was a post-doctoral fellow in Dr. Sharon Dent's lab at the University of Texas MD Anderson Cancer Center and then later in the lab of Dr. C. David Allis at the University of Virginia Health Science Center. After leaving the Allis lab, Jim worked for Upstate Biotechnology (now part of Millipore-Sigma) for six years, directing their efforts commericializing products for epigenetics and chromatin biology research. After leaving Upstate, Jim was a founder of Lake Placid Biologicals, and worked later for Active Motif after their acquisition of the company.

Michael-Christopher Keogh, PhD
Chief Scientific Officer
Michael earned his PhD in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Prior to joining EpiCypher he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression and genetic networks.

Martis Cowles, PhD
Chief Business Officer
Martis is a developmental neuroscientist with a strong background in neuronal development and regeneration. He earned his Bachelor of Science from San Diego State University and began his industry career at Illumina as a research associate in the high-throughput genomics services laboratory. Martis then earned his PhD from the University of California San Diego, studying transcriptional networks that control adult neurogenesis and brain patterning using flatworms as the model organism. Prior to joining EpiCypher in 2015, Dr. Cowles was a Ruth L. Kirschstein postdoctoral fellow in Dr. Eva Anton's laboratory at UNC Chapel Hill where he studied developmental signaling pathways that underlie cortical stem cell function in the developing mouse brain.

Joe McMahon
Board Member
Joe is the President and CEO of Bioventure Partners, a growth advisory and investment firm, serving high-impact, technology driven organizations. Previously, Joe was with KBI Biopharma, a biopharmaceutical CDMO from 2002 until 2016, having served as its President and CEO. During this period, KBI grew from a startup to a 500+ person organization, serving over 300 biopharmaceutical companies globally. In 2015, Joe led the sale of KBI Biopharma to JSR Corporation, a Tokyo-based multinational company. In 2016, Joe also led the sale of kSep Systems (a KBI Biopharma cell therapy technology spinout), to Sartorius AG. Prior to KBI, Joe was a Vice President with Covance Biotechnology Services (a biopharmaceutical CDMO) from 1996 until 2002, including the sale of Covance Biotechnology Services to Akzo Nobel in 2001. Previously, Joe led the engineering and technical services groups for a large medical device company.

Zu-Wen Sun, PhD
Vice President, Product Development
Dr. Sun joined EpiCypher after serving as an Assistant Professor in the Department of Biochemistry at Vanderbilt University School of Medicine. He received a Ph.D. from the LSU Health Sciences Center. He performed his post-doctoral studies with Dr. Michael Hampsey at the UMDNJ - Robert Wood Johnson Medical School and then later with Dr. C. David Allis at the University of Virginia Health Science Center. He is widely recognized for his pioneering work on understanding how histone ubiquitination affects chromatin structure and gene expression.

Mark Kaderli
Key Account Manager - Global
Mark earned a Bachelor of Sciences degree in Bacteriology from UC Davis and spent the first eight years of his industrial career as a Production Manager at Stratagene Cloning Systems, where he was responsible for oligo synthesis, cell biology, PCR and nucleic acid analysis product lines. In 1996, he moved to Austin, Texas to run manufacturing, quality and supply chain operations as VP of Manufacturing for ten years at Ambion, Inc. After the successful sale and integration of Ambion's reagent business by Applied Biosystems, Mark launched a private consulting and contract sales business, representing multiple small start-up biotech companies over the past eleven years. He joined EpiCypher in late 2013 as an internal sales and business development representative.